Registration
|
08:15 - 08:50 |
Welcome note from MarketsandMarkets
|
08:50 - 08:55 |
Opening remarks from the Chairman
|
08:55 - 09:00 |
New Antibody Formats & Cellular Therapy |
Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics
Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics
|
09:00 - 09:30 |
Validated FOXP3 methylation panel to profile culture-induced epigenetic changes at Treg-specific loci
Sarah Miller, Senior Research Associate, EpigenDx
|
09:30 - 10:00 |
Evaluating Efficacy of Novel Antibody and Cell-Based Therapeutics with Next-Generation Mouse Models
Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen
|
10:00 - 10:30 |
Morning Refreshments and Poster Presentations | One-to-One Networking Meetings
|
10:30 - 11:15 |
Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers
Rakesh Dixit, CEO, Bionavigen
|
11:15 - 11:45 |
Veracyte Biopharma Atlas, a comprehensive cancer reference database
Peter Russo, Director, Business Development, Biopharma, Veracyte
|
11:45 - 12:15 |
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics
Ian Pike, Chief Scientific Officer, Proteome Sciences PLC
|
12:15 - 12:45 |
Lunch and Poster Presentations | One-to-One Networking Meetings
|
12:45 - 13:45 |
Deciphering the role of natural killer cells in breast cancer
Isaac Chan, Assistant Professor, UT Southwestern
|
13:45 - 14:15 |
Sanyou Biopharmaceuticals - Global leading integrated R&D service platforms for innovative biologics research
Jin Qiu, Director, Business Development, Sanyou Bio
|
14:15 - 14:45 |
Search for “right” molecule and “right” dose: Case Studies from immuno-oncology portfolio
Ayse Meric Ovacik, Senior Principal Scientist, Genentech
|
14:45 - 15:15 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:15 - 16:00 |
Targeted mRNA for in vivo Reprogrammed off-the-shelf CAR-T Therapies
Dharini Shah, Senior Research Director, Immunology, Sanofi
|
16:00 - 16:30 |
SpliceIO- a robust platform for the discovery and validation of Splicing- derived neoantigens
Gayatri Arun, Vice President, Envisagenics
|
16:30 - 17:00 |
Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736)
Nadia Hassounah, Principal Scientist, Novartis
|
17:00 - 17:30 |
Closing remarks from the Chairman
|
17:30 - 17:30 |
End of Day 1 followed by Drinks Reception and Networking
|
17:30 - 17:30 |